The Efficiency of Adalimumab in Cases of Chronic Methotrexate-Resistant Juvenile Idiopathic Arthritis-Associated Anterior Uveitis: Retrospective Case Series Study

Background: Juvenile idiopathic arthritis (JIA) associated uveitis may be the cause of not only visual acuity decrement, but also blindness. At the same time, in some patients therapy with methotrexate can not prevent the development of these complications.

Objective: Our aim was to investigate the efficiency and safety of using a tumor necrosis factor inhibitor (adalimumab) in patients with JIA-associated uveitis.

Methods: We conducted a retrospective single-arm study of a series of cases. The results of using adalimumab were evaluated in patients with JIA-associated chronic anterior uveitis, who have been under observation for no less than 1 year before and after starting using adalimumab. The latter was prescribed due to progressing and/or recidivous methotrexate-resistant uveitis.

Results: We have analyzed clinical case records of 36 children with JIA-associated uveitis. At the start of therapy with adalimumab, actual uveitis was diagnosed in 30 (83%) patients. Remission was achieved in 29 of 30 cases in 2 (2; 12) weeks in patients with actual uveitis. 11 (31%) patients had a uveitis exacerbation 28 (13; 69) weeks after adalimumab therapy started. Adalimumab reduced the exacerbation frequency from 4 (1; 9) to 0 (0; 1) exacerbations per year for one patient (p < 0,001), and reduced the proportion of patients who were treated with topical glucocorticosteroids (from 83 to 8%). There were no differences (in achieving remission and reducing exacerbation frequency) with regard to patients’ sex, involvement of one or both eyes in the disease onset, antinuclear factor seropositiveness, uveitis type and character of joints affection.

Conclusion: Adalimumab promotes fast and long-lasting remission of JIA-associated methotrexate-resistant uveitis.

1. Saurenmann RK, Levin AV, Feldman BM, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a longterm follow up study. Arthritis Rheum. 2007;56(2):647–657. doi: 10.1002/art.22381.

2. Verazza S, Allegra M, Lattanzi B, et al. Time of onset of iridocyclitis (IC) in children with juvenile idiopathic arthritis (JIA). Pediatr Rheumatol Online J. 2008;6(Suppl 1):77. doi: 10.1186/1546-0096-6-S1-P77.

3. Rosenberg KD, Feuer WJ, Davis JL. Ocular complications of pediatric uveitis. Ophthalmology. 2004;111(12):2299–2306. doi: 10.1016/j.ophtha.2004.06.014.

4. Zannin ME, Buscain I, Vittadello F, et al. Timing of uveitis onset in oligoarticular juvenile idiopathic arthritis (JIA) is the main predictor of severe course uveitis. Acta Ophthalmol. 2012;90(1):91–95. doi: 10.1111/j.1755-3768.2009.01815.x.

5. Angeles-Han ST, Pelajo CF, Vogler LB, et al. Risk markers of juvenile idiopathic arthritis-associated uveitis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. J Rheumatol. 2013;40(12):2088–2096. doi: 10.3899/jrheum.130302.

6. Bou R, Adan A, Borras F, et al. Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus. Rheumatol Int. 2015;35(5):777–785. doi: 10.1007/s00296-015-3231-3.

7. Schiappapietra B, Varnier G, Rosina S, et al. Glucocorticoids in juvenile idiopathic arthritis. Neuroimmunomodulation. 2015; 22(1–2):112–118. doi: 10.1159/000362732.

8. Sen ES, Dick AD, Ramanan AV. Uveitis associated with juvenile idiopathic arthritis. Nat Rev Rheumatol. 2015;11(6):338–348. doi: 10.1038/nrrheum.2015.20.

9. Sedger LM, McDermott MF. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants — past, present and future. Cytokine Growth Factor Rev. 2014;25(4): 453–472. doi: 10.1016/j.cytogfr.2014.07.016.

10. Clarke SL, Sen ES, Ramanan AV. Juvenile idiopathic arthritisassociated uveitis. Pediatr Rheumatol Online J. 2016;14(1):27. doi: 10.1186/s12969-016-0088-2.

11. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392.

12. Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol. 1987;103(2):234–235. doi: 10.1016/s0002-9394(14)74235-7.

13. The Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–516. doi: 10.1016/j.ajo.2005.03.057.

14. Simonini G, Druce K, Cimaz R, et al. Current evidence of anti-tumor necrosis factor alpha treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res (Hoboken). 2014;66(7): 1073–1084. doi: 10.1002/acr.22214.

15. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301(2):418–426. doi: 10.1124/jpet.301.2.418.

16. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91(3):319–324. doi: 10.1136/bjo.2006.103721.

17. Kotaniemi K, Saila H, Kautiainen H. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol. 2011;5:1425–1429. doi: 10.2147/OPTH.S23646.

18. Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013;40(1):74–79. doi: 10.3899/jrheum.120583.

19. Krieckaert C, Rispens T, Wolbink G. Immunogenicity of biolo gical therapeutics: from assay to patient. Curr Opin Rheumatol. 2012; 24(3):306–311. doi: 10.1097/BOR.0b013e3283521c4e.

20. Simonini G, Taddio A, Cattalini M, et al. Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting antiTNF-alpha therapy in childhood chronic uveitis. Pediatr Rheumatol Online J. 2013;11:16. doi: 10.1186/1546-0096-11-16.

21. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):921–926. doi: 10.1136/ard.2006.065615.

22. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(3):711–715. doi: 10.1002/art.21671.

23. Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71(11): 1914–1915. doi: 10.1136/annrheumdis-2012-201544.